Canadian HIV and Viral Hepatitis Pharmacists Network (CHAP) Meetings
CHAP Annual Network Meetings
CHAP meets once a year, in conjunction with the annual Canadian Conference on HIV/AIDS Research (CAHR).
All members are welcome to attend this meeting.
2024 Meeting
2023 Meeting
2022 Meeting
2021 Meeting
2020 Meeting
2019 Meeting
2018 Meeting
2017 Meeting
2016 Meeting
2015 Meeting
2014 Meeting
2013 Meeting
2012 Meeting
2011 Meeting
- 2011 Meeting Agenda
- 2011 Meeting Minutes
- Drug Interaction Cases (R. Therrien)
2010 Meeting
2009 Meeting
- 2009 Meeting Agenda
- 2009 Meeting Minutes
- Update on the 10th International Workshop of Clinical Pharmacology of HIV Therapy (Pierre Giguere)
2008 Meeting
2007 Meeting
2006 Meeting
- 2006 Meeting Agenda
- 2006 Meeting Minutes
- Metabolic Complications of HIV Therapy (Dr. Roger LeBlanc, MD. FRCPC)
- CROI 2006 Conference Update (Alice Tseng, Pharm. D.)
- HIV Pharmacology Workshop 2006 Update (Nancy Sheehan, M.Sc.Phm.)
2005 Meeting
- 2005 Meeting Agenda
- 2005 Meeting Minutes
- Update from the HIV Resistance Workshop, Athens 2005 (Christine)
- HIV Pharmacology Update (Alice, Elizabeth)
- Atazanavir Update (BMS)
- Antiretroviral PK/PD Modeling (Line Labbe)
- Nelfinavir PK in the Aged Study (Nancy)
2004 Meeting
- 2004 Meeting Agenda
- 2004 Meeting Minutes
- 5th International Workshop on Clinical Pharmacology of HIV Therapy(Posters)
- 5th International Workshop on Clinical Pharmacology of HIV Therapy (Oral)
- Atazanavir: Clinical & Metabolic Overview
- The Effect of Atazanavir vs. Lopinavir/Ritonavir on Insulin-Stimulated Glucose Disposal Rate in Healthy Subjects (Poster)
- TDM Case
2003 to 1999 Meetings
Goals:
To promote cross-country sharing of experiences and information to improve patient care.
To develop practical, clinical guidelines on the role of the pharmacist in caring for patients with HIV and/or viral hepatitis.
To collaborate on research protocols which demonstrate positive drug-related outcomes.
To share continuing education resources, in order to make information on HIV and/or viral hepatitis drug therapy more accessible to community, hospital and ambulatory pharmacists, as well as patients.
To foster the development of HIV and/or viral hepatitis pharmacist mentors.
To promote the pharmacists role in HIV and/or viral hepatitis therapeutics on a national level.